NCT01274351View on ClinicalTrials.gov

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

January 25, 2011

Primary Completion Date

August 1, 2019

Study Completion Date

August 1, 2019

Conditions
Chronic Myelogenous Leukemia
Interventions
DRUG

Nilotinib

administered orally at a dose of 300 mg twice daily for 24 months

Trial Locations (13)

16059

Novartis Investigative Site, Bursa

21000

Novartis Investigative Site, Diyarbakır

26480

Novartis Investigative Site, Eskişehir

27310

Novartis Investigative Site, Gaziantep

34093

Novartis Investigative Site, Istanbul

34098

Novartis Investigative Site, Istanbul

34370

Novartis Investigative Site, Okmeydanı

35040

Novartis Investigative Site, Izmir

35340

Novartis Investigative Site, Izmir

38039

Novartis Investigative Site, Talas / Kayseri

61080

Novartis Investigative Site, Trabzon

01330

Novartis Investigative Site, Adana

06100

Novartis Investigative Site, Ankara

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY